Cyclacel Pharmaceuticals, Inc.
(NASDAQ : CYCC)

( )
CYCC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.43%203.201.2%$410.88m
GILDGilead Sciences, Inc.
0.29%73.880.9%$388.27m
CELGCelgene Corporation
-0.26%87.381.2%$331.13m
BIIBBiogen Inc.
0.60%338.911.2%$285.04m
ILMNIllumina, Inc.
-0.15%350.373.5%$238.24m
REGNRegeneron Pharmaceuticals, Inc.
-1.19%383.702.6%$211.99m
EXASExact Sciences Corporation
1.90%74.1425.3%$196.59m
VRTXVertex Pharmaceuticals Incorporated
-0.29%176.601.9%$158.10m
SRPTSarepta Therapeutics, Inc.
-1.06%151.9516.4%$124.69m
AAgilent Technologies, Inc.
0.93%69.571.5%$120.73m
ALXNAlexion Pharmaceuticals, Inc.
0.95%121.972.0%$110.07m
VKTXViking Therapeutics, Inc.
0.98%19.650.9%$100.12m
NKTRNektar Therapeutics
-2.81%56.695.6%$93.69m
ALNYAlnylam Pharmaceuticals, Inc
1.14%94.829.7%$93.23m
BMRNBioMarin Pharmaceutical Inc.
0.21%99.774.4%$92.72m

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products includes CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.